Tofajak XR 11mg Tablet

• Treatment of Ulcerative colitis
• Treatment of Ankylosing spondylitis      
• Treatment of Rheumatoid arthritis
• Treatment of Psoriatic arthritis

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, Tofajak XR 11mg Tablet   also causes some adverse impact on the body, most of which resolved without any medical attention.

Some common side effects include:

• Headache
• Upper respiratory tract infection
• Diarrhea
• Nasopharyngitis (inflammation of the throat and nasal passages)

Seek medical attention in case of any unusual or severe side effects immediately.

• The dosage and treatment duration of the Tofajak XR 11mg Tablet are decided by the doctor according overall patient's health.
• This tablet should be taken with or without food, but at the fix time every day to get effective results. Don't miss a dose or overdose on the medicine.​
  

• Tofajak XR 11mg Tablet is a Janus kinase inhibitor as it contains Tofacitinib as an active ingredient. Janus kinase is a type of enzyme that comes under the category of tyrosine kinase.
• This enzyme is involved in the signaling of cytokine receptors. It's a medicine that blocks the action of Janus kinase, which automatically reduces the activity of the immune system.
• This results in decreased inflammation caused by rheumatic diseases, ulcerative colitis, and other conditions treated by this medicine.​​
  

• Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Su, C., Rousell, S., & Niezychowski, W. (2012). Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. New England Journal of Medicine, 367(7), 616-624. https://pubmed.ncbi.nlm.nih.gov/22894574/
• He, Y., Wong, A. Y., Chan, E. W., Lau, W. C., Man, K. K., Chui, C. S., ... & Wong, I. C. (2013). Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC musculoskeletal disorders, 14(1), 298. https://pmc.ncbi.nlm.nih.gov/articles/PMC3819708/
• Hodge, J. A., Kawabata, T. T., Krishnaswami, S., Clark, J. D., Telliez, J. B., Dowty, M. E., ... & Zwillich, S. (2016). The mechanism of action of tofacitinib-an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol, 34(2), 318-328. https://pubmed.ncbi.nlm.nih.gov/26966791/
• Ytterberg, S. R., Bhatt, D. L., Mikuls, T. R., Koch, G. G., Fleischmann, R., Rivas, J. L., ... & Connell, C. A. (2022). Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. New England Journal of Medicine, 386(4), 316-326. https://pubmed.ncbi.nlm.nih.gov/35081280/
• Sandborn, W. J., Su, C., Sands, B. E., D’Haens, G. R., Vermeire, S., Schreiber, S., ... & Panés, J. (2017). Tofacitinib as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine, 376(18), 1723-1736.
• Dhillon, S. (2017). Tofacitinib: a review in rheumatoid arthritis. Drugs, 77(18), 1987-2001.